Literature DB >> 25084305

Transmitted antiretroviral drug resistance in the men who have sex with men HIV patient cohort, Beijing, China, 2008-2011.

Lili Dai1, Ning Li, Feili Wei, Jingyun Li, Yongjian Liu, Wei Xia, Tong Zhang, Caiping Guo, Wen Wang, Stanley A Schwartz, Supriya D Mahajan, Chiu-Bin Hsiao, Hao Wu.   

Abstract

Transmitted drug resistance (TDR) is an ongoing public health problem in HIV disease treatment. However, little is known about TDR among men who have sex with men (MSM) patients in China. In addition, TDR prevalence among patients with acute HIV infection (AHI) or early HIV infection (EHI) was believed higher than that of patients with chronic HIV infection (CHI), but as AHI is typically either unidentified or crudely defined in large populations, very few direct comparisons have been made. We did a retrospective analysis of TDR in 536 antiretroviral-naive MSM patients from our immunodeficiency clinics at You'an Hospital, Capital Medical University (CMU), in Beijing, China, 2008-2011. The cohort included 266 patients with AHI/EHI and 270 patients with CHI. We analyzed the subtype, estimated the TDR prevalence, and characterized the model of TDR and the predicted drug sensitivity. Additionally, we made a comparison of TDR between the patients with AHI/EHI and patients with CHI. Our results indicated that among the 536 patients, HIV-1 subtype CRF01_AE accounted for 52.1%, subtype B accounted for 24.8%, CRF07_BC/ CRF08_BC accounted for 21.6% (116/536), and 1.3% were denoted as unique recombinant forms (URFs). A total of 7.8% patients had one or more transmitted HIV-1 drug resistance mutations, representing 6.2% for PI-related mutations, 0.9% for NRTI-related mutations, and 1.7% for NNRTI-related mutations. Although patients with AHI/EHI had a higher TDR prevalence as compared to that of patients with CHI, the difference was not statistically significant. There was no significant difference in TDR model and predicted drug susceptibility between the two groups of patients either. This study provides important strategic information for public health planning by healthcare officials in China and warrants a comprehensive study with larger patient cohorts from various healthcare centers within China.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25084305      PMCID: PMC4183911          DOI: 10.1089/vim.2014.0025

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  17 in total

1.  HIV rebounds from latently infected cells, rather than from continuing low-level replication.

Authors:  Beda Joos; Marek Fischer; Herbert Kuster; Satish K Pillai; Joseph K Wong; Jürg Böni; Bernard Hirschel; Rainer Weber; Alexandra Trkola; Huldrych F Günthard
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-20       Impact factor: 11.205

Review 2.  Evolutionary pathways of transmitted drug-resistant HIV-1.

Authors:  Marieke Pingen; Monique Nijhuis; Johan A de Bruijn; Charles A B Boucher; Annemarie M J Wensing
Journal:  J Antimicrob Chemother       Date:  2011-04-18       Impact factor: 5.790

3.  Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006.

Authors:  William H Wheeler; Rebecca A Ziebell; Helena Zabina; Danuta Pieniazek; Joseph Prejean; Ulana R Bodnar; Kristen C Mahle; Walid Heneine; Jeffrey A Johnson; H Irene Hall
Journal:  AIDS       Date:  2010-05-15       Impact factor: 4.177

4.  Public health challenges of the emerging HIV epidemic among men who have sex with men in China.

Authors:  J T F Lau; C Lin; Chun Hao; X Wu; J Gu
Journal:  Public Health       Date:  2011-05       Impact factor: 2.427

5.  New trends of primary drug resistance among HIV type 1-infected men who have sex with men in Liaoning Province, China.

Authors:  Bin Zhao; Xiaoxu Han; Di Dai; Jing Liu; Haibo Ding; Junjie Xu; Zhenxing Chu; Tristan Bice; Yingying Diao; Hong Shang
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-06       Impact factor: 2.205

6.  Differential persistence of transmitted HIV-1 drug resistance mutation classes.

Authors:  Vivek Jain; Maria C Sucupira; Peter Bacchetti; Wendy Hartogensis; Ricardo S Diaz; Esper G Kallas; Luiz M Janini; Teri Liegler; Christopher D Pilcher; Robert M Grant; Rodrigo Cortes; Steven G Deeks; Frederick M Hecht
Journal:  J Infect Dis       Date:  2011-04-15       Impact factor: 5.226

7.  Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART).

Authors:  Loveleen Bansi; Anna Maria Geretti; David Dunn; Teresa Hill; Hannah Green; Esther Fearnhill; Brian Gazzard; Mark Nelson; Kholoud Porter; Andrew Phillips; Caroline Sabin
Journal:  J Acquir Immune Defic Syndr       Date:  2010-04       Impact factor: 3.731

8.  Clinical implications of HIV-1 minority variants.

Authors:  Jonathan Z Li; Daniel R Kuritzkes
Journal:  Clin Infect Dis       Date:  2013-02-27       Impact factor: 9.079

9.  Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007.

Authors:  Christopher B Hurt; Sandra I McCoy; Joann Kuruc; Julie Ae Nelson; Melissa Kerkau; Susan Fiscus; Kara McGee; Joseph Sebastian; Peter Leone; Christopher Pilcher; Charles Hicks; Joseph Eron
Journal:  Antivir Ther       Date:  2009

10.  Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009.

Authors:  Vivek Jain; Teri Liegler; Eric Vittinghoff; Wendy Hartogensis; Peter Bacchetti; Lauren Poole; Lisa Loeb; Christopher D Pilcher; Robert M Grant; Steven G Deeks; Frederick M Hecht
Journal:  PLoS One       Date:  2010-12-10       Impact factor: 3.240

View more
  7 in total

1.  Targeting HIV Prevention Based on Molecular Epidemiology Among Deeply Sampled Subnetworks of Men Who Have Sex With Men.

Authors:  Xicheng Wang; Yasong Wu; Lin Mao; Wei Xia; Weiwei Zhang; Lili Dai; Sanjay R Mehta; Joel O Wertheim; Xingqi Dong; Tong Zhang; Hao Wu; Davey M Smith
Journal:  Clin Infect Dis       Date:  2015-06-30       Impact factor: 9.079

2.  Epidemiological and molecular characteristics of HIV infection among money boys and general men who have sex with men in Shanghai, China.

Authors:  Huamei Yan; Yingying Ding; Frank Y Wong; Zhen Ning; Tony Zheng; Eric J Nehl; Na He
Journal:  Infect Genet Evol       Date:  2015-01-31       Impact factor: 3.342

3.  Prevalence of HIV Antiretroviral Drug Resistance and Its Impacts on HIV-1 Virological Failures in Jiangsu, China: A Cross-Sectional Study.

Authors:  Ying Zhou; Jing Lu; Jinge Wang; Hongjing Yan; Jianjun Li; Xiaoqin Xu; Zhi Zhang; Tao Qiu; Ping Ding; Gengfeng Fu; Xiping Huan; Haiyang Hu
Journal:  Biomed Res Int       Date:  2016-10-11       Impact factor: 3.411

4.  Epidemiological surveillance of HIV-1 transmitted drug resistance among newly diagnosed individuals in Shijiazhuang, northern China, 2014-2015.

Authors:  Xianfeng Wang; Xiaosong Liu; Feng Li; Hong Zhou; Jiefang Li; Yingying Wang; Lihua Liu; Shujun Liu; Yi Feng; Ning Wang
Journal:  PLoS One       Date:  2018-06-05       Impact factor: 3.240

Review 5.  Transmitted Drug Resistance in Antiretroviral Therapy-Naive Persons With Acute/Early/Primary HIV Infection: A Systematic Review and Meta-Analysis.

Authors:  Chunxiang Guo; Yaxin Wu; Yang Zhang; Xinchao Liu; Aixin Li; Meixia Gao; Tong Zhang; Hao Wu; Guanzhi Chen; Xiaojie Huang
Journal:  Front Pharmacol       Date:  2021-11-24       Impact factor: 5.810

6.  Regional Challenges in the Prevention of Human Immunodeficiency Virus Drug Resistance.

Authors:  Catherine Godfrey; Marina Bobkova; Charles Boucher; Giovanni Ravasi; Ping Chen; Fujie Zhang; Yasong Wu; Rami Kantor
Journal:  J Infect Dis       Date:  2017-12-01       Impact factor: 7.759

7.  Transmitted drug resistance in patients with acute/recent HIV infection in Brazil.

Authors:  Ana Cristina G Ferreira; Lara E Coelho; Eduarda Grinsztejn; Carlos S de Jesus; Monick L Guimarães; Valdiléa G Veloso; Beatriz Grinsztejn; Sandra W Cardoso
Journal:  Braz J Infect Dis       Date:  2017-05-21       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.